Trovagene Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference
October 14, 2013 at 05:54 AM EDT
Trovagene, Inc. (NASDAQ: TROV ), a developer of cell-free molecular diagnostics, announced today that two abstracts (#B175 and #B177) highlighting results from studies of the company's novel, non-invasive cancer mutation monitoring platform will be presented on October 21, 2013 at the AACR-NCI-EORTC[1] International Conference on Molecular Targets and Cancer
